Del Rio Alberto

Dr. Alberto Del Rio
Research Associate
Office telephone : 
+39 051 639 8308
Isof 12
Office number: 
Research Unit: 
Research Associates

Chemist, entrepreneur and researcher engaged in medicinal chemistry and drug discovery with an emphasis on cancer biology and targeted therapies in oncology.
Principal investigator of the BioChemoInformatics Unit of the Innovative Methodologies for Organic Synthesis (MISO) group at the ISOF-CNR in Bologna and founder and owner of INNOVAMOL srls, a scientific research and development company specialized in chemical experimental design.
I studied physical chemistry in Modena from 1997 to 2002, theoretical chemistry and computer science in Rennes (2002) and I had my PhD in molecular chemistry and bioactive molecules in Marseilles from 2003 to 2005. I moved to Germany (Erlangen) with an AvH fellowship for a post-doc in chemoinformatics between 2006 and 2007, then, back to Italy - first in Modena and next in Bologna - to start an independent research group.
I am chemical consultant, article reviewer, journal editor, collaborator, mentor, supervisor, lecturer, coordinator of EU and other charity-funded research projects, project evaluator (EU and other agencies) and member of several professional and entrepreneurial associations.


(1) Andreoli, F.; Del Rio, A. Computer-Aided Molecular Design of Compounds Targeting Histone Modifying Enzymes. Comput. Struct. Biotechnol. J. 2015, 13, 358–365.
(2) Iansante, V.; Choy, P. M.; Fung, S. W.; Liu, Y.; Chai, J.-G.; Dyson, J.; Del Rio, A.; D’Santos, C.; Williams, R.; Chokshi, S.; et al. PARP14 Promotes the Warburg Effect in Hepatocellular Carcinoma by Inhibiting JNK1-Dependent PKM2 Phosphorylation and Activation. Nat. Commun. 2015, 6, 7882.
(3) Parenti, M. D.; Bruzzone, S.; Nencioni, A.; Del Rio, A. Selectivity Hot-Spots of Sirtuin Catalytic Cores. Mol. BioSyst. 2015, 11, 2263–2272.
(4) Peserico, A.; Germani, A.; Sanese, P.; Barbosa, A. J.; Di Virgilio, V.; Fittipaldi, R.; Fabini, E.; Bertucci, C.; Varchi, G.; Moyer, M. P.; et al. A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth. J. Cell. Physiol. 2015, 230, 2447–2460.
(5) Sociali, G.; Galeno, L.; Parenti, M. D.; Grozio, A.; Bauer, I.; Passalacqua, M.; Boero, S.; Donadini, A.; Millo, E.; Bellotti, M.; et al. Quinazolinedione SIRT6 Inhibitors Sensitize Cancer Cells to Chemotherapeutics. Eur. J. Med. Chem. 2015, 102, 530–539.
(6) Andreoli, F.; Del Rio, A. Physicochemical Modifications of Histones and Their Impact on Epigenomics. Drug Discov. Today 2014, 19, 1372–1379.
(7) Del Rio, A.; Fernando B, D. C. Molecular Approaches to Explore Natural and Food-Compound Modulators in Cancer Epigenetics and Metabolism. In Foodinformatics: Applications of Chemical Information to Food Chemistry; Martinez-Mayorga, K.; Medina-Franco, J. L., Eds.; Springer International Publishing: Cham, 2014; pp. 131–149.
(8) Masciarelli, S.; Quaranta, R.; Iosue, I.; Colotti, G.; Padula, F.; Varchi, G.; Fazi, F.; Del Rio, A. A Small-Molecule Targeting the MicroRNA Binding Domain of Argonaute 2 Improves the Retinoic Acid Differentiation Response of the Acute Promyelocytic Leukemia Cell Line NB4. ACS Chem. Biol. 2014, 9, 1674–1679.
(9) Parenti, M. D.; Grozio, A.; Bauer, I.; Galeno, L.; Damonte, P.; Millo, E.; Sociali, G.; Franceschi, C.; Ballestrero, A.; Bruzzone, S.; et al. Discovery of Novel and Selective SIRT6 Inhibitors. J. Med. Chem. 2014, 57, 4796–4804.
(10) Andreoli, F.; Barbosa, A. J. M.; Parenti, M. D.; Del Rio, A. Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives. Curr. Pharm. Des. 2013, 19, 578–613.